August 2024's Top Growth Companies With High Insider Confidence

As global markets navigate through a period of economic uncertainty, marked by cooling labor markets and mixed earnings reports, investors are increasingly seeking stability and growth potential in their portfolios. In this environment, companies with high insider ownership often signal strong confidence from those who know the business best, making them attractive options for growth-focused investors.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
People & Technology (KOSDAQ:A137400)	16.5%	35%
Cettire (ASX:CTT)	28.7%	26.7%
Gaming Innovation Group (OB:GIG)	26.7%	37.4%
Medley (TSE:4480)	34%	28.7%
Global Tax Free (KOSDAQ:A204620)	18.1%	72.4%
Seojin SystemLtd (KOSDAQ:A178320)	29.6%	58.7%
Plenti Group (ASX:PLT)	12.8%	106.4%
HANA Micron (KOSDAQ:A067310)	20%	97.4%
Vow (OB:VOW)	31.7%	97.7%
EHang Holdings (NasdaqGM:EH)	32.8%	74.3%

Click here to see the full list of 1465 stocks from our Fast Growing Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

UTour Group (SZSE:002707)

Simply Wall St Growth Rating: ★★★★★★

Overview: UTour Group Co., Ltd. operates in the outbound tourism wholesale and retail sector both within China and internationally, with a market cap of CN¥6.69 billion.

Operations: The company's revenue is derived from its outbound tourism wholesale and retail operations in both domestic and international markets.

Insider Ownership: 23%

UTour Group's earnings are forecast to grow 36.06% annually, outpacing the CN market's 22.2%. Revenue is projected to increase by 36.6% per year, significantly above the market average of 13.6%. Despite a high level of debt, UTour trades at 79.5% below its estimated fair value and recently became profitable. The company’s Return on Equity is expected to reach 25.4% in three years, indicating strong future performance potential amidst substantial insider ownership.

• Click here to discover the nuances of UTour Group with our detailed analytical future growth report.
• In light of our recent valuation report, it seems possible that UTour Group is trading beyond its estimated value.

Fujian Wanchen Biotechnology Group (SZSE:300972)

Simply Wall St Growth Rating: ★★★★★★

Overview: Fujian Wanchen Biotechnology Co., Ltd specializes in the research, development, cultivation, production, and sale of edible fungi in China and has a market cap of CN¥3.60 billion.

Operations: The company's revenue segments include research and development, cultivation, production, and sale of edible fungi in China.

Insider Ownership: 14.9%

Fujian Wanchen Biotechnology Group is forecast to achieve 82.13% annual earnings growth and become profitable within three years, surpassing average market growth. Revenue is expected to grow at 28.4% per year, significantly outpacing the CN market's 13.6%. The company trades at good value relative to peers despite past shareholder dilution. A recent extraordinary shareholders meeting discussed financial aid for a controlled subsidiary, reflecting active insider involvement in strategic decisions.

• Click to explore a detailed breakdown of our findings in Fujian Wanchen Biotechnology Group's earnings growth report.
• In light of our recent valuation report, it seems possible that Fujian Wanchen Biotechnology Group is trading behind its estimated value.

AcrobiosystemsLtd (SZSE:301080)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Acrobiosystems Co., Ltd. develops and manufactures recombinant proteins, antibodies, and biological reagents for pharmaceutical companies, biotechnology firms, and scientific research institutions, with a market cap of CN¥4.36 billion.

Operations: Acrobiosystems Ltd. generates revenue primarily from research and experimental development, amounting to CN¥541.93 million.

Insider Ownership: 37.3%

Acrobiosystems Ltd. is positioned for significant earnings growth, forecasted at 23.53% annually over the next three years, outpacing the CN market's 22.2%. Despite trading at a substantial discount to its estimated fair value, profit margins have declined from last year. Recent initiatives include launching Resilient Supply to enhance cell and gene therapy development and expanding global logistics capabilities for better customer service. However, dividends are not well covered by free cash flows.

• Get an in-depth perspective on AcrobiosystemsLtd's performance by reading our analyst estimates report here.
• The analysis detailed in our AcrobiosystemsLtd valuation report hints at an inflated share price compared to its estimated value.

Next Steps

• Reveal the 1465 hidden gems among our Fast Growing Companies With High Insider Ownership screener with a single click here.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com